ATLANTA, GA--(Marketwired - Mar 31, 2015) - Dutch Gold Resources, Inc. (OTC PINK: DGRI) (the "Company") (http://dutchgoldinc.com) today announced that its subsidiary, Ascendant Therapeutics, Inc., entered the Continuing Medical Education market and will soon launch two accredited courses for healthcare providers in the United States and Canada.
The courses are directed at physicians and nurses who have a need to know about the therapeutic use of MMJ and CBD. The first course analyses the use of CBD on various disease states, and is arranged by systems of the body. The second course addresses the use of THC related therapies and is appropriate for healthcare providers in states that have legalized the use of MMJ.
The exploration of how cannabinoid receptors and phytocannabinoids interact in disease processes and the possibilities for prevention and medical management of disorders utilizing adjunctive Cannabidiol (CBD) from legal industrial hemp is critical for all health care practitioners, including physicians, nurse practitioners, nurses, chiropractors, and dentists. We are pleased to have developed CME courses that will give physicians and nurses ACCME credit for their education in this emerging field.
While the marketing of the CME courses will begin Q2 2015, the Company is pleased to announce that it has entered into an agreement that will provide scholarships for 1,500 physicians, resulting in revenue that will be booked for each quarter of 2015 and into 2016.
Further the Company plans to release each of the manuals that have been previously announced, one in April and one in May of 2015.
Forward-Looking Statements
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Dutch Gold Resources, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.